Medscape InDiscussion: Chronic Kidney Disease

S2 Episode 3: Does Your Patient Have IgA Nephropathy?Experts Drs Matthew A. Sparks and Dana V. Rizk discuss the pathology, presentation, and management of IgA nephropathy. Looking for the latest on clinical trials and approved treatments? Tune in! Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/991603). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Chronic Kidney Disease (CKD) https://emedicine.medscape.com/article/238798-overview IgA Nephropathy https://emedicine.medscape.com/article/239927-overview Polycystic Kidney Disease https://emedicine.medscape.com/article/244907-overview Biomarkers for IgA Nephropathy on the Basis of Multi-Hit Pathogenesis https://pubmed.ncbi.nlm.nih.gov/29740706/ Galactose-Deficient IgA1 as a Candidate Urinary Marker of IgA Nephropathy https://pubmed.ncbi.nlm.nih.gov/35683557/ Immunological Drivers of IgA Nephropathy: Exploring the Mucosa-Kidney Link https://pubmed.ncbi.nlm.nih.gov/34821031/ Nephrotic Syndrome https://emedicine.medscape.com/article/244631-overview Podocytopathies https://pubmed.ncbi.nlm.nih.gov/32792490/ Minimal-Change Disease https://emedicine.medscape.com/article/243348-overview IgA Vasculitis (Henoch-Schönlein Purpura) https://emedicine.medscape.com/article/984105-overview Sodium-Glucose Transport Protein 2 (SGLT2) Inhibitors https://www.ncbi.nlm.nih.gov/books/NBK576405/ Dapagliflozin in Patients With Chronic Kidney Disease https://pubmed.ncbi.nlm.nih.gov/32970396/ Empagliflozin in Patients With Chronic Kidney Disease https://pubmed.ncbi.nlm.nih.gov/36331190/ A Controlled Trial of Fish Oil in IgA Nephropathy. Mayo Nephrology Collaborative Group https://pubmed.ncbi.nlm.nih.gov/7935657/ Fish Consumption, Omega 3 Fatty Acids and Cardiovascular Disease. The Science and the Clinical Trials https://pubmed.ncbi.nlm.nih.gov/19326716/ Tonsillectomy in a European Cohort of 1,147 Patients With IgA Nephropathy https://pubmed.ncbi.nlm.nih.gov/26586175/ Sparsentan in Patients With IgA Nephropathy: A Prespecified Interim Analysis From a Randomised, Double-Blind, Active-Controlled Clinical Trial https://pubmed.ncbi.nlm.nih.gov/37015244/ Intensive Supportive Care Plus Immunosuppression in IgA Nephropathy https://pubmed.ncbi.nlm.nih.gov/26962737/ Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial https://pubmed.ncbi.nlm.nih.gov/28763548/ Targeted-Release Budesonide Versus Placebo in Patients With IgA Nephropathy (NEFIGAN): A Double-Blind, Randomised, Placebo-Controlled Phase 2b Trial https://pubmed.ncbi.nlm.nih.gov/28363480/ Results From Part A of the Multi-Center, Double-Blind, Randomized, Placebo-Controlled NefIgArd Trial, Which Evaluated Targeted-Release Formulation of Budesonide for the Treatment of Primary Immunoglobulin A Nephropathy https://pubmed.ncbi.nlm.nih.gov/36270561/ Crescents and IgA Nephropathy: A Delicate Marriage https://pubmed.ncbi.nlm.nih.gov/35806856/ Crescentic, Proliferative IgA Nephropathy: Clinical and Histological Response to Methylprednisolone and Intravenous Cyclophosphamide https://pubmed.ncbi.nlm.nih.gov/12808169/ Hydroxychloroquine Inhibits Macrophage Activation and Attenuates Renal Fibrosis After Ischemia-Reperfusion Injury https://pubmed.ncbi.nlm.nih.gov/33936063/ New Treatment Strategies for IgA Nephropathy: Targeting Plasma Cells as the Main Source of Pathogenic Antibodies https://pubmed.ncbi.nlm.nih.gov/35628935/

28min

S2 Episode 4: Chronic Kidney Disease: FSGS, Genetic Testing, and APOL1Join Drs Matthew Sparks and Kirk Campbell as they dive into the murky waters of focal segmental glomerular sclerosis. How do you diagnose? How do you treat? Tune in to find out. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/991604). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Chronic Kidney Disease (CKD) https://emedicine.medscape.com/article/238798-overview Focal Segmental Glomerulosclerosis https://emedicine.medscape.com/article/245915-overview Membranoproliferative Glomerulonephritis https://emedicine.medscape.com/article/240056-overview Membranous Glomerulonephritis https://emedicine.medscape.com/article/239799-overview Collapsing Focal Segmental Glomerulosclerosis in Viral Infections https://pubmed.ncbi.nlm.nih.gov/35095882/ Novel Treatment Paradigms: Focal Segmental Glomerulosclerosis https://pubmed.ncbi.nlm.nih.gov/36644367/ Glomerular Diseases (GD) https://kdigo.org/guidelines/gd/ A Review of Podocyte Biology https://pubmed.ncbi.nlm.nih.gov/29852492/ APOL1 Nephropathy: From Genetics to Clinical Applications https://pubmed.ncbi.nlm.nih.gov/32616495/ A Study to Test BI 764198 in People With a Type of Kidney Disease Called Primary Focal Segmental Glomerulosclerosis https://classic.clinicaltrials.gov/ct2/show/NCT05213624 Efficacy and Safety of ACE Inhibitor and Angiotensin Receptor Blocker Therapies in Primary Focal Segmental Glomerulosclerosis Treatment: A Systematic Review and Meta-Analysis https://pubmed.ncbi.nlm.nih.gov/35518835/ Sodium-Glucose Transport Protein 2 (SGLT2) Inhibitors https://www.ncbi.nlm.nih.gov/books/NBK576405/ Calcineurin Inhibitors in the Treatment of Primary Focal Segmental Glomerulosclerosis: A Protocol of Systematic Review and Meta-Analysis of Randomized Controlled Trials https://pubmed.ncbi.nlm.nih.gov/33530282/ Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease https://pubmed.ncbi.nlm.nih.gov/33186054/ IgA Nephropathy https://emedicine.medscape.com/article/239927-overview Impact of Diabetes on the Effects of Sodium Glucose Co-Transporter-2 Inhibitors on Kidney Outcomes: Collaborative Meta-Analysis of Large Placebo-Controlled Trials https://pubmed.ncbi.nlm.nih.gov/36351458/ African Trypanosomiasis (Sleeping Sickness) https://emedicine.medscape.com/article/228613-overview Lupus Nephritis https://emedicine.medscape.com/article/330369-overview Inaxaplin for Proteinuric Kidney Disease in Persons With Two APOL1 Variants https://pubmed.ncbi.nlm.nih.gov/36920755/ Phase 2/3 Adaptive Study of VX-147 in Adults and Adolescents With APOL1-Mediated Proteinuric Kidney Disease https://classic.clinicaltrials.gov/ct2/show/NCT05312879 Antisense Oligonucleotides: An Emerging Area in Drug Discovery and Development https://pubmed.ncbi.nlm.nih.gov/32604776/ Janus Kinase-STAT Inhibition to Reduce APOL1 Associated Kidney Disease (JUSTICE) https://classic.clinicaltrials.gov/ct2/show/NCT05237388 APOL1 Long-Term Kidney Transplantation Outcomes Network (APOLLO) (APOLLO) https://classic.clinicaltrials.gov/ct2/show/NCT03615235 Nephrotic Syndrome Study Network (NEPTUNE) https://repository.niddk.nih.gov/studies/neptune/

27min

Episodes

Lyssna när som helst, var som helst

Andra podcasts du kanske gillar...